Stock Events

Stock Events

Cybin Inc 

$8.28
477
+$0.10+1.22% Friday 21:00
+$0.00+0%Saturday 01:00Pre-market

Statistics

Day High
8.38
Day Low
8.14
52W High
10.72
52W Low
4.81
Volume
716,528
Avg. Volume
873,573
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Next
-2
-1.34
-0.68
-0.02
Expected EPS
-0.73908242672
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-160.34MNet Income

Analyst Ratings

34.00Average Price Target
The highest estimate is 70.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.84B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Cybin's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap1.9B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor to Cybin.
GH Research
GHRS
Mkt Cap1.82B
GH Research is involved in the development of therapeutics based on DMT for depression, competing in the same psychedelic treatment space as Cybin.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including psilocybin and MDMA, competing in the mental health treatment market alongside Cybin.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics is exploring the use of psychedelics for the treatment of various conditions, including mental health disorders, making it a competitor to Cybin.
PSYC
PSYC
Mkt Cap135,518
Psyched Wellness is focused on the development of psychedelic products, including Amanita Muscaria, competing in the broader psychedelic wellness market.
TripAdvisor
TRIP
Mkt Cap1.63B
Red Light Holland is involved in the production, growth, and sale of a premium brand of magic truffles, competing in the psychedelic substances market relevant to Cybin's interests.

About

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Eric So L.L.B.
Employees
50
Country
United States
ISIN
CA23256X1006

Listings

STU
DE
R7E.STU
MU
DE
R7E1.MU
STU
DE
R7E1.STU
MU
DE
R7E.MU

0 Comments

Share your thoughts

FAQ

What is Cybin Inc stock price today?▼
The current price of CYBN is $8.28 USD — it has increased by +1.22% in the past 24 hours. Watch Cybin Inc stock price performance more closely on the chart.
What is Cybin Inc stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Cybin Inc stocks are traded under the ticker CYBN.
Is Cybin Inc stock price growing?▼
CYBN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cybin Inc has showed a +13.42% increase.
What is Cybin Inc revenue for the last year?▼
Cybin Inc revenue for the last year amounts to 0 USD.
What is Cybin Inc net income for the last year?▼
CYBN net income for the last year is -160.34M USD.
How many employees does Cybin Inc have?▼
As of July 30, 2026, the company has 50 employees.
In which sector is Cybin Inc located?▼
Cybin Inc operates in the Health & Wellness sector.
When did Cybin Inc complete a stock split?▼
The last stock split for Cybin Inc was on September 19, 2024 with a ratio of 1:38.
Where is Cybin Inc headquartered?▼
Cybin Inc is headquartered in Toronto, United States.